Dyadic International (Dyadic International) EBIT : $-8.19 Mil (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Dyadic International EBIT?

Dyadic International's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-2.17 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.19 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Dyadic International's annualized ROC % for the quarter that ended in Dec. 2023 was -1,583.93%. Dyadic International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -5,899.32%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Dyadic International's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -22.72%.

Dyadic International EBIT Historical Data

The historical data trend for Dyadic International's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dyadic International EBIT Chart

Dyadic International Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-9.26

-9.96

-14.63

-10.12

-8.19

Dyadic International Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-2.21	-2.04	-2.28	-1.71	-2.17

Competitive Comparison of Dyadic International's EBIT

For the Biotechnology subindustry, Dyadic International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dyadic International's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dyadic International's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Dyadic International's EV-to-EBIT falls into.

Dyadic International EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.19 Mil.

Dyadic International (NAS:DYAI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Dyadic International's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-8.672 * ( 1 - 0% )	/	( (0.405	+	0.69)	/ 2 )
=	-8.672	/	0.5475
=	-1,583.93 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	9.256	-	1.22	-	( 8.176	-	max(0, 1.457	-	9.088	+	8.176	))
=	0.405

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8.219	-	1.714	-	( 7.263	-	max(0, 2.252	-	8.067	+	7.263	))
=	0.69

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Dyadic International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-8.672	/	( ( (0.153 + max(-0.687, 0))	+	(0.141 + max(-1.465, 0)) )	/	2 )
=	-8.672	/	( ( 0.153	+	0.141 )	/	2 )
=	-8.672	/	0.147
=	-5,899.32 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.239	+	0	+	0.484)	-	(1.22	+	0.19	+	2.2204460492503E-16)
=	-0.687

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.411	+	0	+	0.328)	-	(1.714	+	0.49	+	0)
=	-1.465

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Dyadic International's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-8.191	/	36.045
	=	-22.72 %

Dyadic International EBIT Related Terms

Thank you for viewing the detailed overview of Dyadic International's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Dyadic International (Dyadic International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyadic International Inc (NAS:DYAI) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

140 Intracoastal Pointe Drive, Suite 404, Jupiter, FL, USA, 33477

Website

https://www.dyadic.com

Dyadic International Inc is a global biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

Executives

Ronen Tchelet	officer: VP of Research and Bus. Dvlpmt	140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Mark A Emalfarb	director, 10 percent owner, officer: President, CEO & Chairman	C/O DYADIC INTERNATIONAL, INC., 140 INTRACOASTAL POINT DRIVE, SUITE 404, JUPITER FL 33477-5094
Joseph P Hazelton	officer: Chief Business Officer	140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER FL 33477
Francisco Trust Under Agreement Dated February 28, 1996	10 percent owner	C/O ROBERT S. LEVIN, ESQ., TRUSTEE, 180 NORTH LASALLE STREET, SUITE 3200, CHICAGO IL 60601
Patrick K. Lucy	director	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Matthew S. Jones	officer: Managing Dir of BD & Licensing	140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Seth Herbst	director	140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Barry Buckland	director	C/O DYADIC INTERNATIONAL, INC., 140 INTERCOASTAL POINTE DR SUITE 404, JUPITER FL 33477
Ping Wang Rawson	officer: Chief Financial Officer	140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Michael P. Tarnok	director	KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Arindam Bose	director	4452 BELTWAY DRIVE, ADDISON TX 75001
Jack Kaye	director	C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022
Tom Juda	10 percent owner	410 S LUCERNE BLVD, LOS ANGELES CA 90020
John Steven Emerson	10 percent owner	1522 ENSLEY AVENUE, LOS ANGELES CA 90024
Nancy Juda	10 percent owner	410 S LUCERNE BLVD, LOS ANGELES CA 90020